片仔癀(600436.SH)：温肺定喘颗粒Ⅱ期临床试验完成首例受试者入组

Core Viewpoint - The company Pianzaihuang (600436.SH) has initiated a Phase II clinical trial for its product "Wenfei Dingchuan Granules," targeting chronic obstructive pulmonary disease (COPD) during the stable period, marking a significant step in its research and development efforts [1] Group 1: Clinical Trial Details - The clinical trial is randomized, double-blind, placebo-controlled, dose-exploratory, and multi-center [1] - The first subject has been enrolled, officially commencing the Phase II clinical research [1] Group 2: Product Information - Wenfei Dingchuan Granules are derived from clinical experience and aim to treat symptoms associated with lung and kidney qi deficiency and phlegm-stasis obstructing the lungs [1] - The intended functions include "tonifying the lungs, warming the kidneys, stopping cough, relieving asthma, resolving phlegm, and removing stasis" [1] - Symptoms targeted by the product include cough, sputum, wheezing, fatigue, lower back and knee soreness, aversion to wind, cold intolerance, and specific tongue and pulse characteristics [1]